BRMS1、整合素β_1及p-AKT在卵巢癌组织中的表达及临床意义  

Expression and clinical significance of BRMS1 and integrin β_1,p-AKT in ovarian carcinoma and their relationships with clinicopathological features

作　　者：饶玉梅[1] 陈刚[2] 李留霞[1] 余静丽[1] 李秀芳[1] 

机构地区：[1]郑州大学第一附属医院妇产科,河南郑州450002 [2]华中科技大学附属同济医院妇产科,湖北武汉430030

出　　处：《中国当代医药》2013年第23期9-11,共3页China Modern Medicine

基　　金：国家自然科学基金(81272859);郑州大学第一附属医院青年创新基金

摘　　要：目的研究乳腺癌转移抑制因子1(BRMS1)、整合素β1、p-AKT在卵巢癌中的表达及其与临床病理特征的关系。方法应用免疫组织化学法检测卵巢癌、良性肿瘤及其卵巢组织中BRMS1、整合素β1、p-AKT的表达。结果 BRMS1在卵巢癌中阳性表达率降低(P<0.01),其表达与卵巢癌转移相关,与组织学分级无关。整合素β1及p-AKT在卵巢癌中的阳性表达率升高(P<0.01),其表达与卵巢癌病理分期、分化程度有关(P<0.05)。BRMS1与整合素β1及p-AKT在卵巢癌组织中表达呈负相关(r=-0.59,r=-0.50,P<0.05)。结论卵巢癌中BRMS1有可能通过抑制整合素β1/AKT通路,抑制肿瘤转移。Objective To explore the expression of BRMS1and integrin β 1,p-AKT in ovarian cancer,and their relationships with clinicopathological features.Methods SP immanohistochemistrical method was utilized to detect the level of BRMS1,integrin β 1 and p-AKT in normal ovarian tissue,benign ovarian tumor and ovarian adenocarcinoma.Results BRMS1 positive expression in ovarian cancer was decreased（P＆lt;0.01）;Its expression was associated with ovarian cancer metastasis,had nothing to do with histologic grading.Integrin beta 1 and p-AKT in the positive expression rate of ovari an cancer increased（P＆lt;0.01）;Its expression was associated with ovarian cancer pathological staging and differentiation degree（P＆lt;0.05）.BRMS1 with integrin beta 1,p-AKT expressed in ovarian cancer tissue showed a negative correlation（r=-0.59,r=-0.50,P＆lt;0.05）.Conclusion BRMS1 might be in cooperation with integrin β 1 /p-AKT signal pathway to inhibit the metastasis function of the ovarian cancer.

关 键 词：乳腺癌转移抑制因子1 整合素Β1 P-AKT 卵巢癌 

分 类 号：R737.31[医药卫生—肿瘤]